Behind the scenes, as tumors progress and gain resistance to treatment, a protein called YB-1 quietly gives directions. Now, researchers at Oregon Health & Science University have developed a first-of-its-kind drug that inhibits YB-1, effectively silencing those orders.

Related Keywords

Oregon , United States , Shivaani Kummar , Arpit Dheeraj , Sanjay Malhotra , Oregon Health Science University , School Of Medicine , Knight Cancer Institute , Cell Reports Medicine , Oregon Health , Science University , Experimental Therapeutics , Cell Reports ,